Keck School Faculty

Lon Schneider, MD
Lon Schneider, MD
Professor of Psychiatry & the Behavioral Sciences
Psychiatry and The Behavioral Sciences
CHP-216 1540 Alcazar Street Health Sciences Campus Los Angeles
Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health). In addition, he is principal investigator of the National Institute of Mental Health's CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer's disease.

Woodward/White, Inc.: The Best Doctors in America, 1992-2009

A randomized clinical trial to evaluate home-based assessment of people over 75 years old Alzheimers Dement. 2019 May; 15(5):615-624. . View in PubMed

A randomized clinical trial to evaluate home-based assessment of people over 75 years old Alzheimers Dement. 2019 Mar 11. . View in PubMed

Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction Nat Med. 2019 Feb; 25(2):270-276. . View in PubMed

Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction Nat Med. 2019 Jan 14. . View in PubMed

Evaluation of Medicare Claims Data as a Tool to Identify Dementia J Alzheimers Dis. 2019; 67(2):769-778. . View in PubMed

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease Alzheimers Dement (N Y). 2019; 5:20-26. . View in PubMed

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis JAMA Netw Open. 2018 Nov 02; 1(7):e184080. . View in PubMed

Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions Alzheimers Res Ther. 2018 Jan 15; 10(1):4. . View in PubMed

Analysis of shared heritability in common disorders of the brain Science. 2018 06 22; 360(6395). . View in PubMed

(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease Curr Alzheimer Res. 2018; 15(9):883-891. . View in PubMed

(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease Curr Alzheimer Res. 2018 01 10. . View in PubMed

Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions Alzheimers Res Ther. 2018 01 15; 10(1):4. . View in PubMed

Dementia prevention, intervention, and care Lancet. 2017 Dec 16; 390(10113):2673-2734. . View in PubMed

Challenging Assumptions About African American Participation in Alzheimer Disease Trials Am J Geriatr Psychiatry. 2017 Oct; 25(10):1150-1159. . View in PubMed

Characterizing Highly Benefited Patients in Randomized Clinical Trials Int J Biostat. 2017 May 20; 13(1). . View in PubMed

Dementia research priorities-1 - Author's reply Lancet Neurol. 2017 Mar; 16(3):181. . View in PubMed

Dementia research priorities-2 - Author's reply Lancet Neurol. 2017 Mar; 16(3):182. . View in PubMed

Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E e4 Carriers: A Review JAMA Neurol. 2017 Mar 01; 74(3):339-347. . View in PubMed

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease Alzheimers Res Ther. 2017 Feb 17; 9(1):10. . View in PubMed

Dementia research priorities-1 - Author's reply Lancet Neurol. 2017 03; 16(3):181. . View in PubMed

Dementia research priorities-2 - Author's reply Lancet Neurol. 2017 03; 16(3):182. . View in PubMed

Alzheimer's disease and other dementias: update on research Lancet Neurol. 2017 01; 16(1):4-5. . View in PubMed

Alzheimer's disease and other dementias: update on research Lancet Neurol. 2017 Jan; 16(1):4-5. . View in PubMed

Characterizing Highly Benefited Patients in Randomized Clinical Trials Int J Biostat. 2017 05 20; 13(1). . View in PubMed

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study Am J Psychiatry. 2016 May 01; 173(5):473-80. . View in PubMed

Defeating Alzheimer's disease and other dementias: a priority for European science and society Lancet Neurol. 2016 Apr; 15(5):455-532. . View in PubMed

Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64. . View in PubMed

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109. . View in PubMed

Accelerating stem cell trials for Alzheimer's disease Lancet Neurol. 2016 Feb; 15(2):219-230. . View in PubMed

Accelerating stem cell trials for Alzheimer's disease Lancet Neurol. 2016 02; 15(2):219-230. . View in PubMed

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial Lancet. 2016 12 10; 388(10062):2873-2884. . View in PubMed

Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial Int Psychogeriatr. 2015 Dec; 27(12):2059-67. . View in PubMed

Estimating Mortality Associated With Antipsychotics and Other Psychotropics--Reply JAMA Psychiatry. 2015 Oct; 72(10):1058. . View in PubMed

Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment Alzheimers Dement (N Y). 2015 Jun; 1(1):63-71. . View in PubMed

Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm JAMA Psychiatry. 2015 May; 72(5):438-45. . View in PubMed

Differences in Alzheimer disease clinical trial outcomes based on age of the participants Neurology. 2015 Mar 17; 84(11):1121-7. . View in PubMed

Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement. 2015 Jan; 11(1):24-31.. View in PubMed

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future Expert Rev Neurother. 2015 Jan; 15(1):83-105. . View in PubMed

Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study JAMA Neurol. 2014 Nov; 71(11):1394-404. . View in PubMed

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. . View in PubMed

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Lancet Neurol. 2014 Jul; 13(7):676-85. . View in PubMed

Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease Alzheimers Dement. 2014 May; 10(3):349-59. . View in PubMed

Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study J Am Geriatr Soc. 2014 May; 62(5):985-8. . View in PubMed

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial JAMA. 2014 Feb 19; 311(7):682-91. . View in PubMed

A new roadmap for drug development for Alzheimer's disease Nat Rev Drug Discov. 2014 Feb; 13(2):156. . View in PubMed

Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial PLoS One. 2014; 9(6):e98426. . View in PubMed

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement. 2013 Jul; 9(4):438-44. . View in PubMed

Alzheimer disease pharmacologic treatment and treatment research Continuum (Minneap Minn). 2013 Apr; 19(2 Dementia):339-57. . View in PubMed

Early intervention with an estrogen receptor ß-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease J Alzheimers Dis. 2013; 37(2):403-19. . View in PubMed

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44. . View in PubMed

Ginkgo and AD: key negatives and lessons from GuidAge Lancet Neurol. 2012 Oct; 11(10):836-7. . View in PubMed

Caregiver burden, health utilities, and institutional service use in Alzheimer's disease Int J Geriatr Psychiatry. 2012 Apr; 27(4):382-93. . View in PubMed

Discontinuing donepezil or starting memantine for Alzheimer's disease N Engl J Med. 2012 Mar 08; 366(10):957-9. . View in PubMed

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. . View in PubMed

Biomarker positive and negative subjects in the ADNI cohort: clinical characterization Curr Alzheimer Res. 2012 12; 9(10):1135-41. . View in PubMed

Citalopram for agitation in Alzheimer's disease: design and methods Alzheimers Dement. 2012; 8(2):121-30. . View in PubMed

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease J Clin Psychiatry. 2012 Jan; 73(1):121-8. . View in PubMed

Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress Free Radic Biol Med. 2011 Dec 01; 51(11):2007-17. . View in PubMed

Estrogen receptor ß-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause Menopause. 2011 Oct; 18(10):1131-42. . View in PubMed

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. . View in PubMed

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD Am J Psychiatry. 2011 Aug; 168(8):831-9. . View in PubMed

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83.. View in PubMed

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet. 2011 May; 43(5):436-41. . View in PubMed

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. . View in PubMed

Anti-aß therapeutics in Alzheimer's disease: the need for a paradigm shift Neuron. 2011 Jan 27; 69(2):203-13. . View in PubMed

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. . View in PubMed

Fixing Alzheimer disease trials by improving process and methods Curr Alzheimer Res. 2010 Nov; 7(7):564-5. . View in PubMed

Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates Am J Geriatr Psychiatry. 2010 Oct; 18(10):917-27. . View in PubMed

Caregiver burden, health utilities, and institutional service costs among community-dwelling patients with Alzheimer disease Alzheimer Dis Assoc Disord. 2010 Oct-Dec; 24(4):380-9. . View in PubMed

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 Alzheimers Dement. 2010 Mar; 6(2):89-97. . View in PubMed

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA. 2009 Dec 16; 302(23):2557-64. . View in PubMed

Current Alzheimer's disease clinical trials: methods and placebo outcomes Alzheimers Dement. 2009 Sep; 5(5):388-97. . View in PubMed

Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7. . View in PubMed

Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis Int J Geriatr Psychiatry. 2009 May; 24(5):539-44. . View in PubMed

Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008" A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimers Dement. 2009 Mar; 5(2):172-9. . View in PubMed

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimers Dement. 2009 Mar; 5(2):85-92. . View in PubMed

Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease Int J Geriatr Psychiatry. 2009 Jan; 24(1):96-105. . View in PubMed

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial Am J Psychiatry. 2008 Jul; 165(7):844-54. . View in PubMed

Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence Am J Geriatr Psychiatry. 2008 Jul; 16(7):558-67. . View in PubMed

Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria Am J Geriatr Psychiatry. 2008 Jun; 16(6):469-77. . View in PubMed

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement. 2008 May; 4(3):156-63. . View in PubMed

Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. 2008 Apr; 7(4):287-9.. View in PubMed

American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementiasSecond edition. Am J Psychiatry. 2007 Dec; 164(12 Suppl):5-56. . View in PubMed

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease Arch Gen Psychiatry. 2007 Nov; 64(11):1259-68. . View in PubMed

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials Lancet Neurol. 2007 Sep; 6(9):782-92. . View in PubMed

Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Curr Alzheimer Res. 2007 Jul; 4(3):273-6.. View in PubMed

Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease" Wuthering forest plots: distinguishing the forest from the plots. Alzheimers Dement. 2007 Jan; 3(1):18-20. . View in PubMed

Design of Depression in Alzheimer's Disease Study-2 Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30. . View in PubMed

Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice Brain Res. 2006 Oct 20; 1116(1):194-200. . View in PubMed

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease N Engl J Med. 2006 Oct 12; 355(15):1525-38. . View in PubMed

ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38. . View in PubMed

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials Am J Geriatr Psychiatry. 2006 Mar; 14(3):191-210. . View in PubMed

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type Curr Alzheimer Res. 2005 Dec; 2(5):541-51. . View in PubMed

Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):279-83. . View in PubMed

Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease' Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27. . View in PubMed

AD2000: donepezil in Alzheimer's disease Lancet. 2004 Jun 26; 363(9427):2100-1. . View in PubMed

Estrogen and dementia: insights from the Women's Health Initiative Memory Study JAMA. 2004 Jun 23; 291(24):3005-7. . View in PubMed

Delay in nursing home placement with donepezil J Am Geriatr Soc. 2004 Jun; 52(6):1024-6; author reply 1026-7. . View in PubMed

Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses Psychiatr Clin North Am. 2003 Dec; 26(4):971-90, x-xi. . View in PubMed

Cholinesterase inhibitors for vascular dementia? Lancet Neurol. 2003 Nov; 2(11):658-9.. View in PubMed

Efficacy of controlled-release paroxetine in the treatment of late-life depression J Clin Psychiatry. 2003 Sep; 64(9):1065-74. . View in PubMed

Choosing treatment for Alzheimer's patients and their caregivers Geriatrics. 2003 Aug; 58 Suppl 1:3-18, 23; quiz 19-22. . View in PubMed

An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression Am J Psychiatry. 2003 Jul; 160(7):1277-85. . View in PubMed

Cholinesterase inhibitors for Alzheimer disease JAMA. 2003 May 14; 289(18):2359-60; author reply 2360-1. . View in PubMed

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease Curr Drug Targets. 2003 Feb; 4(2):97-112. . View in PubMed

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial Schizophr Bull. 2003; 29(1):57-72. . View in PubMed

Evidence-based practices in geriatric mental health care Psychiatr Serv. 2002 Nov; 53(11):1419-31. . View in PubMed

Galantamine for vascular dementia: some answers, some questions Lancet. 2002 Apr 13; 359(9314):1265-6. . View in PubMed

Antidepressant Treatment of Very Old Patients Am J Geriatr Psychiatry. 1993 Winter; 1(1):21-29. . View in PubMed

Powered by SC CTSI
Go to Top